

## MIRIKIZUMAB

2020

Miri-phase 2  
UC

RCT phase 2/ Mirikizumab IV 50mg, 200mg or 600mg or placebo at w0,4 & 8/ UC/ Induction

Conclusion:

**Mirikizumab was effective in inducing a clinical response after 12 weeks in UC. Mirikizumab showed durable efficacy throughout the maintenance period.**

2022

Miri-phase 2  
CD

RCT phase2 / Mirikizumab 200mg,600mg,1000mg IV or pbo q4w & 300mgSC mainten/ CD/ Ind&Maint

Conclusion:

**Mirikizumab effectively induced endoscopic response after 12 weeks in patients with moderate-to-severe CD and demonstrated durable efficacy to Week 52.**

2023

LUCENT

RCT phase3 / Mirikizumab 300mg vs placebo induction & 200mg maintenance q4w/ UC/ Induct&Maint

Conclusion:

**Mirikizumab was more effective than placebo in inducing and maintaining clinical remission in patients with mod-severely active UC. Opportunistic infection or cancer occurred in a small number of patients treated with mirikizumab.**